1. Home
  2. ICUCW vs JKS Comparison

ICUCW vs JKS Comparison

Compare ICUCW & JKS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ICUCW
  • JKS
  • Stock Information
  • Founded
  • ICUCW N/A
  • JKS 2006
  • Country
  • ICUCW United States
  • JKS China
  • Employees
  • ICUCW 19
  • JKS N/A
  • Industry
  • ICUCW Biotechnology: Pharmaceutical Preparations
  • JKS Semiconductors
  • Sector
  • ICUCW Health Care
  • JKS Technology
  • Exchange
  • ICUCW Nasdaq
  • JKS Nasdaq
  • Market Cap
  • ICUCW N/A
  • JKS N/A
  • IPO Year
  • ICUCW 2021
  • JKS 2010
  • Fundamental
  • Price
  • ICUCW $0.03
  • JKS $18.93
  • Analyst Decision
  • ICUCW
  • JKS Hold
  • Analyst Count
  • ICUCW 0
  • JKS 5
  • Target Price
  • ICUCW N/A
  • JKS $27.19
  • AVG Volume (30 Days)
  • ICUCW N/A
  • JKS 522.5K
  • Earning Date
  • ICUCW N/A
  • JKS 04-29-2025
  • Dividend Yield
  • ICUCW N/A
  • JKS 15.85%
  • EPS Growth
  • ICUCW N/A
  • JKS N/A
  • EPS
  • ICUCW N/A
  • JKS N/A
  • Revenue
  • ICUCW N/A
  • JKS $11,445,691,729.00
  • Revenue This Year
  • ICUCW N/A
  • JKS N/A
  • Revenue Next Year
  • ICUCW N/A
  • JKS $36.29
  • P/E Ratio
  • ICUCW N/A
  • JKS N/A
  • Revenue Growth
  • ICUCW N/A
  • JKS N/A
  • 52 Week Low
  • ICUCW N/A
  • JKS $13.42
  • 52 Week High
  • ICUCW N/A
  • JKS $37.36
  • Technical
  • Relative Strength Index (RSI)
  • ICUCW N/A
  • JKS 55.72
  • Support Level
  • ICUCW N/A
  • JKS $18.32
  • Resistance Level
  • ICUCW N/A
  • JKS $18.97
  • Average True Range (ATR)
  • ICUCW 0.00
  • JKS 0.73
  • MACD
  • ICUCW 0.00
  • JKS -0.01
  • Stochastic Oscillator
  • ICUCW 0.00
  • JKS 61.14

About ICUCW SeaStar Medical Holding Corporation Warrant

SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. The Company is comprised of a single reportable segment, which is its Device Segment.

Share on Social Networks: